Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC

作者：Luis Paz‐Ares, Rémi Veillon, Margarita Majem, Caicun Zhou, Kejing Tang, Sang-We Kim, Gary Richardson, Nicolas Girard, Rachel E. Sanborn, Aaron S. Mansfield, Keunchil Park, Julia Schuchard, Joris Diels, Jan Sermon, Archan Bhattacharya, Patricia Lorenzini, Honeylet Wortman‐Vayn, Roland E. Knoblauch, Trishala Agrawal, Mahadi Baig, Akira Ono, Joshua K. Sabari · 发表于：Lung Cancer · 年份：2025 · DOI：10.1016/j.lungcan.2025.108788 · 被引用次数：1 · 研究领域：Lung Cancer Treatments and Mutations、Cancer Immunotherapy and Biomarkers、Lung Cancer Research Studies